<DOC>
	<DOCNO>NCT00787722</DOCNO>
	<brief_summary>This study design examine whether treat Devic 's disease patient high dose cyclophosphamide together rATG/rituximab ( drug reduce function immune system ) , follow return previously collect patient 's stem cell result improvement Devic 's disease . Stem cell undeveloped cell capacity grow mature blood cell , normally circulate blood stream . The purpose intense chemotherapy destroy cell patient 's immune system , may cause his/her disease . The purpose stem cell infusion produce normal immune system longer attack patient 's body . The purpose study examine safety efficacy treatment . The drug use study treatment drug commonly use immune suppression .</brief_summary>
	<brief_title>Hematopoietic Stem Cell Transplant Devic 's Disease</brief_title>
	<detailed_description>Neuromyelitis optica ( NMO , Devic 's disease ) autoimmune , inflammatory , demyelinate central nervous system disorder person 's immune system attack optic nerve spinal cord characterize concurrence optic neuritis transverse myelitis , typically associate lesion spinal cord extend three vertebral segment . Although commonly relapse , distinct multiple sclerosis severe , tend spare brain , associate longitudinally extensive lesion spinal cord MRI . Furthermore , NMO associate highly specific serum autoantibody marker , NMO-IgG , target water channel aquaporin-4 . The disease follow relapse course 90 % patient . At present , parenteral corticosteroid widely employ first-line treatment optic neuritis myelitis attack , whereas therapeutic plasmapheresis apply case corticosteroid failure . Various strategy prevention NMO relapse employ small case series modest activity . Immune base therapy , order effective , need start early disease course Devic 's disease predominantly immune-mediated inflammatory disease . Since 50 % patient NMO confine wheelchair within 5 year onset , new therapy need disease . We propose , phase I study , complete immune ablation subsequent reconstitution autologous stem cell . Based experience pilot study , current protocol mobilize stem cell granulocyte-colony stimulating factor ( G-CSF ) cyclophosphamide collect stem cell apheresis . A subsequent bone marrow harvest perform need supplement peripheral blood stem cell ( PBSC ) . Based experience autoimmune flare patient receive G-CSF alone mobilization , patient mobilize cyclophosphamide 2.0 g/m2 G-CSF 5- 10 mcg /kg . In order avoid cumulative cardiac toxicity cyclophosphamide allow culture HSC product , three week must separate administration cyclophosphamide mobilization conditioning . Cyclophosphamide 50 mg/kg/day give IV 2 hour 500 cc normal saline . If actual weight &lt; ideal weight , cyclophosphamide give base actual weight . If actual weight &gt; ideal weight , cyclophosphamide give adjusted weight . Adjusted weight = ideal weight + 25 % ( actual weight minus ideal weight ) . Hydration-guidelines , NS 150-200 ml/hr give 2 hour cyclophosphamide continue 24 hour last cyclophosphamide dose . The rate hydration aggressively adjust . BID weight obtain . Amount fluid modify base patient 's fluid status . r ATG 0.5 mg/kg give day -5 , 1.0 mg/kg give day -4 , 1.5 mg/kg give day -3 -1. r ATG infuse 10 hour . Premedicate Acetaminophen 650 mg po Diphenhydramine 25 mg po/IV 30 minute infusion . Rituxan ( Rituximab ) - The dose 500 mg Rituximab dilute 500 ml 0.9 % NS infuse per standard Rituximab infusion guideline , give day -6 day + 1 . Following guideline , Rituximab start 50 mg/hr . If reaction occur , dose increase 50 mg/hr every 30 minute maximum 400 mg/hr . G-CSF - guideline , 5-10 mcg/kg/day start day + 5 continued absolute neutrophil count reach least 1,000/Âµl .</detailed_description>
	<mesh_term>Neuromyelitis Optica</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Age 1665 , time pretransplant evaluation An establish diagnosis Devic 's disease ( one acute attack ) NMO IgG aquaporin4 autoantibody positive Paraplegia quadriplegia legal blindness ( define visual acuity 20/200 less good eye best correction possible ) Any illness opinion investigator would jeopardize ability patient tolerate aggressive chemotherapy Prior history malignancy except localize basal cell , squamous skin cancer carcinoma situ cervix . Other malignancy patient judge cure , head neck cancer , breast cancer consider individual basis Positive pregnancy test Inability unwillingness pursue effective mean birth control . Effective birth control define 1 ) refrain act vaginal intercourse ( ABSTINENCE ) ; 2 ) consistent use birth control pills ; 3 ) injectable birth control method ( Depoprovera , Norplant ) ; 4 ) tubal sterilization male partner undergone vasectomy ; 5 ) placement IUD ( intrauterine device ) ; 6 ) use , every act intercourse , diaphragm contraceptive jelly and/or condom contraceptive foam Failure willingly accept comprehend irreversible sterility side effect therapy FEV1/FVC &lt; 60 % predict bronchodilator therapy ( necessary ) DLCO &lt; 50 % predict Resting LVEF &lt; 50 % Serum creatinine &gt; 2.0 mg/dl Known hypersensitivity mouse , rabbit , E. Coli derive protein Presence metallic object implant body would preclude ability patient safely MRI exams Bilirubin &gt; 2.0 mg/dl Platelet count &lt; 100,000/ul ANC &lt; 1000/ul Psychiatric illness , mental deficiency cognitive dysfunction make compliance treatment inform consent impossible Active infection except asymptomatic bacteriuria Inability give inform consent HIV positive Transaminases &gt; 3x normal limit , liver cirrhosis</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>High dose immunosuppressive therapy</keyword>
	<keyword>Hematopoietic stem cell support</keyword>
</DOC>